ClinicalTrials.gg
TerminatedNCT01597570Updated Jul 25, 2017

Effectiveness and Safety Confirmation Between FASTSEAL® Bioabsorbable VCD and Perclose® ProGlide SMC System

A Phase 3 interventional study of Vascular Closure Device in The Patients Who Needed Hemostasis at the Puncture Site of Common Femoral Artety(CFA) Caused by Femoral Angiogram or Intervention After the Catheter Removal, sponsored by Taewoong Medical Co., Ltd.. Terminated at 2 sites in Korea, Republic of. Open to participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-07-25.

Sponsored by Taewoong Medical Co., Ltd. (part of Olympus Corporation) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

It is purposed to verify a superiority of the Fastseal® Bioabsorbable Vascular Access Closure System through effectiveness and safety confirmation of hemostasis (TTH; Time to hemstasis) and ambulation (TTA; Time to ambulation) at the puncture site of common femoral artery (CFA) after the procedures of Fastseal® Biosorbable Vascular Access Closure System or Perclose® ProGlide Suture-Mediated Closure System during 1 month observation.

Read the detailed description

Prospective, Single blind, randomized

Comparative study using the Fastseal® Bioabsorbable Vascular Access Closure System as an investigational device and the Perclose® ProGlide Suture-Mediated Closure System as a comparator.

After going through the confirmation of inclusion/exclusion criteria with signed subjects, they will have a procedure either of the two devices. The subjects should follow designated physician's instructions accurately during the clinical trial period.There are about 6 times evaluations Including screening.

02

Conditions studied

  • The Patients Who Needed Hemostasis at the Puncture Site of Common Femoral Artety(CFA) Caused by Femoral Angiogram or Intervention After the Catheter Removal
03

In context

Lead sponsor

Taewoong Medical Co., Ltd. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.

First submitted before Taewoong Medical Co., Ltd. became part of Olympus Corporation.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Between 20 years old and 85 years old, randomized
  • Patient who submitted a written for the this trial
  • The subjects should be scheduled to have an angiography or intervention through the common femoral artery (CFA).
  • The subjects must be used a 6Fr sheath of the Terumo's RadiFocus Introducer II.

Exclusion criteria

Exclusion Criteria:

  • In case of the subject has a functure site in both legs.
  • The patient who had the closing device insertion or manual compression at the targeted femoral artery within 30 days
  • Patients with severe bleeding disorders (Severe bleeding history, blood coagulation disorder, thrombocytopenia (under 100,000 of count), hemophilia, anemia (\<10g/dL, Hct\<30%), Thrombasthenia, any related bleeding disorder
  • Hypertension patient BP ≥180/110mmHg
  • In case of thrombolysis(ex: streptokinase, urokinase, t-PA) within 24hr
  • If there is any hematoma, arteriovenous fistula(AVF), false aneurysm existed at the access site of femoral artery
  • Severe obesity > 40kg/m2
  • In case of prior stent placement or artificial vessel insertion in the common femoral artery(CFA)
  • Under 5mm of Common femoral artery (CFA) diameter
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    FASTSEAL® Bioabsorbable VCD

    Fastseal® Bioabsorbable Vascular Access Closure System

    Device: Vascular Closure Device

  • Active comparator
    Perclose® ProGlide SMC System

    Perclose® ProGlide Suture-Mediated Closure System

    Device: Vascular Closure Device

Interventions

  • DeviceVascular Closure Device

    To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site

    Also known as: FASTSEAL® Bioabsorbable Vascular Access Closure System /, Perclose® ProGlide Suture-Mediated Closure System

06

What researchers measure

Primary outcomes

  1. TTH; Time to hemostasis

    Time interval between procedure and hemostasis

    Time frame: From the procedure start - 1m 30s, 2m 30s, 3m 30s, 4m 30s, 6m 30s, 8m 30s, 10m 30s

Secondary outcomes

  1. TTA(Time to ambulation) & Failure rate of hemostasis

    Time interval between procedure and ambulation

    Time frame: From the procedure start - 2hr, 4hr, 6hr, 8hr, 12hr

07

Study locations

2 sites
  • Samsung Medical Center
    Seoul, Irwon-Dong, Gangnam-Gu 130-710, Korea, Republic of
  • Severance Hospital
    Seoul, Seodaemun Gu 120-752, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Dec 2012 and a completion of Dec 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2012
First posted
May 14, 2012
Start
May 2012
Primary completionActual
Dec 10, 2012
CompletionActual
Dec 10, 2012
Last update
Jul 25, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01597570
Responsible party
Sponsor
First posted
May 14, 2012
Start date
May 2012
Primary completion
Dec 10, 2012
Completion
Dec 10, 2012
Last update
Jul 25, 2017

Study contacts

Dongik Kim, Professor Dr.
principal investigator · Severance Hospital / Radiology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion